Senior Correspondent, London
Ben's Feed
Apr 20, 2014
Apr 17, 2014
Apr 17, 2014
Apr 17, 2014

GSK, facing bribery claims, battles to build new sales model

LONDON (Reuters) – Drugmaker GlaxoSmithKline (GSK.L: Quote, Profile, Research, Stock Buzz) – hit by bribery claims in five countries – is to employ hundreds more doctors as members of staff as it seeks to build a new sales model designed to eliminate sharp marketing practices.

Following a decision to cut commercial ties with outside doctors, GSK expects to increase its in-house team of physicians by 10-20 percent over the next year or so from around 1,500 at present, Chief Medical Officer James Shannon told Reuters.

Apr 17, 2014
Apr 17, 2014
Apr 16, 2014

New kind of trial aims to speed cancer drug development

LONDON (Reuters) – Scientists and drugmakers are pioneering a new kind of clinical trial that changes the way cancer drugs are studied, potentially cutting both the time and cost of bringing them to market.

Instead of testing one drug at a time, a novel lung cancer study announced on Thursday will allow British researchers to test up to 14 drugs from AstraZeneca and Pfizer at the same time within one trial.

Apr 16, 2014
Apr 16, 2014
Apr 15, 2014
    • About Ben

      "Ben Hirschler is European pharmaceuticals, biotechnology and healthcare correspondent, based in London. Previously, he was in charge of British company news and before that was posted to Johannesburg, covering the economic challenges facing post-apartheid South Africa."
    • More from Ben

    • Follow Ben